CD274 and B-cell chronic lymphocytic leukemia: These findings were further validated in patient-derived xenograft (PDX) models showing an enhanced anti-CLL activity by combining avadomide and anti-PD-1 or anti-PD-1 ligand (PD-L1) (245).